Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U01AI186861 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | NIH |
| Infectious Diseases Research Collaboration, Uganda | OTHER |
| Ministry of Health, Uganda | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
The CRITICal study aims to estimate the effectiveness of intermittent preventive treatment in school children (IPTsc) with dihydroartemisinin-piperaquine (DP) for reducing community level malaria burden. Given that school-aged children are the primary drivers of transmission, the study hypothesis is that IPTsc will reduce this infectious reservoir and thus the burden of malaria in persons of all ages in surrounding communities.
The CRITICal study is an open label, phase IV, cluster-randomized trial to evaluate the effectiveness of IPTsc with DP administered approximately every 2 months to children attending primary school. Clusters are geographically defined target areas surrounding government-run health facilities previously established and referred to as Malaria Reference Centers (MRCs). A total of 24 clusters (MRCs) will be included in the study. These clusters were selected based on participation in an on-going sentinel site malaria surveillance network in areas with moderate-high malaria transmission intensity. Clusters will be randomized in a 1:1 ratio such that all primary schools serving the populations of each target area will either receive IPTsc or not receive IPTsc. The intervention will be delivered for 2 years and evaluations will continue for 1 additional year after the intervention is stopped. The primary outcome of the study will be malaria incidence within the population of the target areas. Secondary outcomes will include the the prevalence of parasitemia and molecular markers of DP resistance at the community level; the prevalence of parasitemia, anemia, and school attendance among children attending primary school; and estimates of the cost-effectiveness of IPTsc.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| IPTsc | Experimental | DP will be administered approximately every 2 months for two years to all eligible children enrolled in primary schools serving the target areas from clusters randomized to the interventional arm. |
|
| No IPTsc | No Intervention | No IPTsc (standard of care) |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| dihydroartemisinin-piperaquine | Drug | D-Artepp, is manufactured by Guilin Pharmaceutical Co Ltd, and is prequalified by the WHO and approved for use in Uganda by the National Drug Authority. Standard treatment doses of DP (once a day x 3 days) will be administered using weight-based guidelines targeting a total dose of 6.4 mg/kg dihydroartemisinin and 51.2 mg/kg of piperaquine as per manufacturer's instructions. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of cases of laboratory-confirmed malaria diagnosed among patients residing in the target area during the period the intervention is implemented | malaria incidence: the number of cases of laboratory-confirmed malaria diagnosed at the MRC among patients residing in the target area, per unit time, divided by the total population of the target area in patients of all ages over the 24-month intervention period | 24 months after intervention implemented |
| Measure | Description | Time Frame |
|---|---|---|
| Number of cases of laboratory-confirmed malaria diagnosed among patients residing in the target area after the intervention is competed | malaria incidence: the number of cases of laboratory-confirmed malaria diagnosed at the MRC among patients residing in the target area, per unit time, divided by the total population of the target area in patients of all ages 12 months after intervention is completed |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Grant Dorsey, MD, PhD | Contact | 415-310-0525 | grant.dorsey@ucsf.edu | |
| Tamara Clark, MHS | Contact | 415-517-3444 | tamara.clark@ucsf.edu |
| Name | Affiliation | Role |
|---|---|---|
| Grant Dorsey, MD, PhD | University of California, San Francisco | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Infectious Diseases Research Collaboration | Kampala | Uganda |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008288 | Malaria |
| ID | Term |
|---|---|
| D011528 | Protozoan Infections |
| D010272 | Parasitic Diseases |
| D007239 | Infections |
| D000096724 | Mosquito-Borne Diseases |
Not provided
Not provided
This study will be an open label, phase IV, cluster-randomized trial to evaluate the effectiveness of IPTsc with DP administered approximately every 2 months to children attending primary school. Clusters are geographically defined target areas surrounding government-run health facilities previously established and referred to as Malaria Reference Centers (MRCs). A total of 24 clusters (MRCs) will be included in the study. These clusters were selected based on participation in an on-going sentinel site malaria surveillance network in areas with moderate-high malaria transmission intensity. Clusters will be randomized in a 1:1 ratio such that all primary schools serving the populations of each target area will either receive IPTsc or not receive IPTsc.
Not provided
Not provided
Not provided
Not provided
|
|
| 12 months after intervention is completed |
| Parasite prevalence among community residents 12 months after the intervention is implemented | Proportion of blood smears positive for parasites by microscopy at the time of community cross-sectional surveys | 12 months after the intervention is implemented |
| Parasite prevalence among community residents 24 months after the intervention is implemented | Proportion of blood smears positive for parasites by microscopy at the time of community cross-sectional surveys | 24 months after the intervention is implemented |
| Parasite prevalence among community residents 12 months after the intervention is completed | Proportion of blood smears positive for parasites by microscopy at the time of community cross-sectional surveys | 12 months after the intervention is completed |
| Prevalence of molecular markers of DP resistance from parasite positive samples from community surveys 12 months after the intervention is implemented | Proportion of parasite positive samples with molecular markers of DP resistance detected | 12 months after the intervention is implemented |
| Prevalence of molecular markers of DP resistance from parasite positive samples from community surveys 24 months after the intervention is implemented | Proportion of parasite positive samples with molecular markers of DP resistance detected | 24 months after the intervention is implemented |
| Prevalence of molecular markers of DP resistance from parasite positive samples from community surveys 12 months after the intervention is completed | Proportion of parasite positive samples with molecular markers of DP resistance detected | 12 months after the intervention is completed |
| Parasite prevalence among schoolchildren 12 months after the intervention is implemented | Proportion of blood smears positive for parasites by microscopy at the time of school surveys | 12 months after the intervention is implemented |
| Parasite prevalence among schoolchildren 24 months after the intervention is implemented | Proportion of blood smears positive for parasites by microscopy at the time of school surveys | 24 months after the intervention is implemented |
| Parasite prevalence among schoolchildren 12 months after the intervention is completed | Proportion of blood smears positive for parasites by microscopy at the time of school surveys | 12 months after the intervention is completed |
| Anemia prevalence among schoolchildren 12 months after the intervention is implemented | Proportion of children with anemia at the time of school surveys Anemia defined based on WHO criteria as:
| 12 months after the intervention is implemented |
| Anemia prevalence among schoolchildren 24 months after the intervention is implemented | Proportion of children with anemia at the time of school surveys Anemia defined based on WHO criteria as:
| 24 months after the intervention is implemented |
| Anemia prevalence among schoolchildren 12 months after the intervention is completed | Proportion of children with anemia at the time of school surveys Anemia defined based on WHO criteria as:
| 12 months after the intervention is completed |
| D000079426 |
| Vector Borne Diseases |